Loading...
XASXBOT
Market cap430mUSD
Dec 23, Last price  
0.38AUD
1D
0.00%
1Q
2.70%
Jan 2017
763.64%
Name

Botanix Pharmaceuticals Ltd

Chart & Performance

D1W1MN
XASX:BOT chart
P/E
—
P/S
1,147.68
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
14.57%
Rev. gr., 5y
-33.67%
Revenues
602k
-34.23%
8640000000000001,777,9184,685,8867,573,8566,887,1982,754,835914,973601,820
Net income
-14m
L+51.52%
2,098-2,798,876-3,416,963-2,825,253-3,043,463-1,988,608-1,519,744-1,568,030-1,846,460-1,131,036-1,014,541-1,708,377-4,773,098-11,011,813-17,039,211-16,730,708-3,334,001-13,170,749-9,153,974-13,869,709
CFO
-8m
L-32.69%
-2,844,053-3,014,832-2,751,180-2,375,070-1,618,608-861,118-692,970-1,117,656-1,039,860-1,290,368-1,203,857-6,688-4,639,927-9,909,009-13,140,723-17,358,586-2,968,023-11,184,055-12,074,064-8,127,281
Dividend
Oct 03, 19960.0479291045 AUD/sh
Earnings
Feb 26, 2025

Profile

Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase IIb clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. The company was incorporated in 1984 and is based in Leederville, Australia.
URL
https://botanixpharma.com/
IPO date
Jan 24, 1985
Employees
11
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
602
-34.23%
915
-66.79%
2,755
-60.00%
Cost of revenue
12,444
13,711
18,436
Unusual Expense (Income)
NOPBT
(11,843)
(12,796)
(15,681)
NOPBT Margin
Operating Taxes
(3,669)
(2,755)
Tax Rate
NOPAT
(11,843)
(9,126)
(12,926)
Net income
(13,870)
51.52%
(9,154)
-30.50%
(13,171)
295.04%
Dividends
Dividend yield
Proceeds from repurchase of equity
95,098
20,714
BB yield
-18.36%
-13.81%
Debt
Debt current
122
Long-term debt
122
Deferred revenue
Other long-term liabilities
Net debt
(79,308)
(10,313)
(7,103)
Cash flow
Cash from operating activities
(8,127)
(12,074)
(11,184)
CAPEX
(113)
(7,054)
(2,922)
Cash from investing activities
(17,999)
(7,054)
(2,922)
Cash from financing activities
95,098
22,030
(152)
FCF
(10,006)
(10,856)
(12,827)
Balance
Cash
79,308
10,250
7,286
Long term investments
63
62
Excess cash
79,278
10,267
7,210
Stockholders' equity
108,733
22,951
8,152
Invested Capital
29,455
12,684
1,065
ROIC
ROCE
EV
Common stock shares outstanding
1,501,564
1,153,952
973,142
Price
0.35
165.38%
0.13
128.07%
0.06
-28.75%
Market cap
518,039
245.33%
150,014
170.45%
55,469
-28.73%
EV
438,731
139,701
48,367
EBITDA
(11,770)
(12,685)
(15,537)
EV/EBITDA
Interest
11
82
37
Interest/NOPBT